See what 10M+ investors are talking about. Get the Stocktwits Daily Rip for what retail is watching right now, free to your inbox<\/a> <\/p>\n Retatrutide’s A1C Reduction In Focus <\/p>\n
In the Transcend-T2D-2 trial involving 1,298 patients, Retatrutide reduced A1C, a measure of average blood sugar levels, by 2.2 percentage points after 80 weeks, compared with 1.8 points for Ozempic’s highest approved 2 mg dose. Patients on Retatrutide also lost an average of 44 to 47 pounds, compared with about 21 pounds on Ozempic. <\/p>\n
Retatrutide is a once-weekly injection that targets three hormone receptors, GLP-1, GIP, and glucagon, to help regulate blood sugar and appetite. Lilly is planning to seek U.S. Food and Drug Administration (FDA) approval for obesity in early 2027. <\/p>\n
The trial compared Retatrutide with injectable Ozempic 2 mg, the highest approved dose. <\/p>\n
“Based on these results and those from across our Phase 3 program, we believe Retatrutide, if approved, could shift the treatment paradigm for people living with type 2 diabetes, obesity and related cardiometabolic conditions,” said Kenneth Custer, Executive Vice President and President of Lilly Cardiometabolic Health. <\/p>\n
Lilly And Novo’s Weight-Loss Drug Race <\/p>\n
Novo and Lilly already have two blockbuster weight-loss drugs each on the market and are developing newer treatments as the market expands rapidly. Morgan Stanley expects the global GLP-1 market for diabetes and obesity treatments to reach $190 billion by 2035. <\/p>\n
Lilly has found strong success with its obesity drugs Mounjaro and Zepbound, with second-quarter (Q2) Mounjaro sales surging 91% to $9.94 billion and Zepbound revenue climbing 46% to $4.93 billion. <\/p>\n
Retatrutide could become the next major revenue driver for Lilly. S&P Global Market Intelligence estimates Retatrutide’s potential peak annual global sales at $25.34 billion by 2037. <\/p>\n","protected":false},"excerpt":{"rendered":"Retatrutide reduced A1C by 2.2 percentage points, compared with 1.8 percentage points for Ozempic. Lilly plans to seek…\n","protected":false},"author":2,"featured_media":644798,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[33],"tags":[2169,138,553,219,246,5932,134,329,37332,5933,5483,524,16400,7454,111,139,69,244,8499,13081,294,781,5934,5935,643,37333,7496,37334],"class_list":["post-644797","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-401k","tag-business","tag-business-news","tag-economy","tag-finance","tag-financial-information","tag-health","tag-investing","tag-investment-tools","tag-investor","tag-market-news","tag-medication","tag-mortgage","tag-mutual-funds","tag-new-zealand","tag-newzealand","tag-nz","tag-personal-finance","tag-quote","tag-real-estate","tag-retirement","tag-stock","tag-stock-research","tag-stock-valuation","tag-stocks","tag-suze-orman","tag-tax","tag-track-portfolio"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/644797","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/comments?post=644797"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/posts\/644797\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media\/644798"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/media?parent=644797"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/categories?post=644797"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/nz\/wp-json\/wp\/v2\/tags?post=644797"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}